An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Trial Profile

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Obinutuzumab (Primary) ; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 19 Sep 2016 Status changed from recruiting to completed.
    • 27 Aug 2013 Actual initiation date changed form May 2013 to Aug 2013 as reported by ClinicalTrials.gov.
    • 11 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top